R21 CA109057/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2007	5
2008	4
2009	1
2010	1
2011	2
2021	0

1

Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

Wang Y, Kreisberg JI, Ghosh PM. Wang Y, et al. Curr Cancer Drug Targets. 2007 Sep;7(6):591-604. doi: 10.2174/156800907781662248. Curr Cancer Drug Targets. 2007. PMID: 17896924 Review.

2

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Jathal MK, Chen L, Mudryj M, Ghosh PM. Jathal MK, et al. Immunol Endocr Metab Agents Med Chem. 2011 Jun;11(2):131-149. doi: 10.2174/187152211795495643. Immunol Endocr Metab Agents Med Chem. 2011. PMID: 21603064 Free PMC article.

3

Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.

Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL, deVere White RW, Ghosh PM. Chen L, et al. Clin Cancer Res. 2011 Oct 1;17(19):6218-28. doi: 10.1158/1078-0432.CCR-11-1548. Epub 2011 Aug 15. Clin Cancer Res. 2011. PMID: 21844010 Free PMC article.

4

AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer.

Mikhailova M, Wang Y, Bedolla R, Lu XH, Kreisberg JI, Ghosh PM. Mikhailova M, et al. Adv Exp Med Biol. 2008;617:397-405. doi: 10.1007/978-0-387-69080-3_38. Adv Exp Med Biol. 2008. PMID: 18497063

5

Reduced expression of epidermal growth factor receptors in rat liver during aging.

Kamat A, Ghosh PM, Glover RL, Zhu B, Yeh CK, Choudhury GG, Katz MS. Kamat A, et al. J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):683-92. doi: 10.1093/gerona/63.7.683. J Gerontol A Biol Sci Med Sci. 2008. PMID: 18693222 Free PMC article.

6

Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases.

Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Bedolla RG, et al. Clin Cancer Res. 2009 Feb 1;15(3):788-96. doi: 10.1158/1078-0432.CCR-08-1402. Clin Cancer Res. 2009. PMID: 19188148 Free PMC article.

7

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM. Chen L, et al. Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29. Cancer Res. 2010. PMID: 20587519 Free PMC article.

8

The oncogenic potential of a prostate cancer-derived androgen receptor mutant.

Shi XB, Xue L, Tepper CG, Gandour-Edwards R, Ghosh P, Kung HJ, DeVere White RW. Shi XB, et al. Prostate. 2007 May 1;67(6):591-602. doi: 10.1002/pros.20544. Prostate. 2007. PMID: 17262801

9

Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Wang Y, et al. Oncogene. 2008 Nov 27;27(56):7106-17. doi: 10.1038/onc.2008.318. Epub 2008 Sep 8. Oncogene. 2008. PMID: 18776922 Free PMC article.

10

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.

Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN Jr, de Vere White RW. Vinall RL, et al. Clin Cancer Res. 2007 Oct 15;13(20):6204-16. doi: 10.1158/1078-0432.CCR-07-0600. Clin Cancer Res. 2007. PMID: 17947488 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results